German digital health SME developing biomarker-based technology to detect and prevent workplace burnout and chronic stress.
SOMA Analytics is a German digital health SME specializing in the detection and prevention of workplace stress and burnout. Their core work involves developing technology-based tools — likely mobile or wearable — that monitor chronic stress biomarkers and translate physiological signals into actionable workplace health interventions. They successfully followed the SME Instrument pathway from a Phase 1 feasibility study to a full Phase 2 development and market-entry project, indicating they moved from research concept to commercial product development. Their focus is squarely on occupational health and employee well-being, positioned at the intersection of health data, behavioral analytics, and HR technology.
Both H2020 projects — 'Chronic Stress Biomarkers for Early Detection and Prevention of Burnout' (2014) and 'The Smart Way to Beat Stress at Work' (2016) — center directly on identifying and mitigating occupational stress.
The 2014 SME-1 project explicitly targeted chronic stress biomarkers as measurable indicators for early burnout detection.
SOMA completed both Phase 1 (€50K feasibility) and Phase 2 (€1.88M development) of the EU SME Instrument, demonstrating full-cycle product development capability.
Both projects focus on the workplace as the deployment context, targeting employers and employees rather than clinical or hospital settings.
SOMA Analytics ran only two projects within a tightly bounded 2014–2018 window, both on the same core theme, so there is no meaningful divergence in focus over time. What the timeline does reveal is a maturation arc: the 2014 project was a proof-of-concept study on biomarker identification, while the 2016 project scaled that into a full commercial solution ("The Smart Way to Beat Stress at Work"), backed by nearly €1.9M in EU funding. No H2020 activity appears after 2018, which may indicate the company transitioned fully into commercial operations, pivoted, or ceased activity — it is not possible to determine which from this data alone.
SOMA followed a deliberate SME Instrument scale-up path — feasibility to full development — suggesting a product-oriented company that, by 2018, was likely focused on commercial go-to-market rather than further EU R&D funding.
SOMA Analytics operated exclusively as coordinator across both projects, with no recorded consortium partners. This points to a company that works independently — either as a solo applicant under the SME Instrument (which is designed for single-company applications) or with very limited external collaboration. For potential partners, this means SOMA is likely comfortable leading and self-directing technical work, but may have limited experience integrating into multi-partner consortia.
No consortium partners or cross-country collaborations are recorded in the H2020 data. This is consistent with the SME Instrument funding scheme, which is specifically designed for individual SMEs rather than consortia, so the absence of partners does not indicate isolation — it reflects the funding structure they chose.
SOMA Analytics holds a rare position as an SME that successfully completed the full EU SME Instrument cycle — from Phase 1 feasibility to Phase 2 commercialization — in the niche field of workplace stress technology. This dual achievement signals genuine technical credibility and EU-validated commercial potential, not just research interest. For anyone building a consortium around digital occupational health, SOMA represents a specialist with both scientific grounding in stress biomarkers and a demonstrated ability to translate research into a market-ready product.
